 | • レポートコード：D0JU09104 • 出版社/出版日：Transparency Market Research / 2020年2月20日 • レポート形態：英文、PDF、182ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、臓器移植後拒絶反応治療薬の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場動向、市場概要、薬物クラス別（カルシニューリン阻害剤、抗増殖剤、mTOR阻害剤、抗体、ステロイド）分析、移植種類別（腎臓移植、骨髄移植、肝臓移植、心臓移植、肺移植、その他の移植）分析、流通経路別（病院薬局、小売薬局、オンライン薬局）分析、地域別分析、競争状況などの構成でお届けいたします。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場動向 ・市場概要 ・臓器移植後拒絶反応治療薬の世界市場：薬物クラス別（カルシニューリン阻害剤、抗増殖剤、mTOR阻害剤、抗体、ステロイド） ・臓器移植後拒絶反応治療薬の世界市場：移植種類別（腎臓移植、骨髄移植、肝臓移植、心臓移植、肺移植、その他の移植） ・臓器移植後拒絶反応治療薬の世界市場：流通経路別（病院薬局、小売薬局、オンライン薬局） ・臓器移植後拒絶反応治療薬の世界市場：地域別 ・競争状況 |
Organ Transplant Rejection Medications Market – Scope of the Report
TMR’s report on the global organ transplant rejection medications market studies past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the market during the forecast period from 2019 to 2027. The report provides the overall market revenue of the global organ transplant rejection medications market for the period of 2017–2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global organ transplant rejection medications market during the forecast period.
The report has been prepared after an extensive primary and secondary research. Primary research involves bulk of research efforts wherein, analysts carry out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global organ transplant rejection medications market.
Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global organ transplant rejection medications market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global organ transplant rejection medications market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global organ transplant rejection medications market.
The report delves into the competition landscape of the global organ transplant rejection medications market. Key players operating in the global organ transplant rejection medications market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the global organ transplant rejection medications market that have been profiled in this report.
Key Questions Answered in Organ Transplant Rejection Medications Market Report
What is the scope of growth of companies in the organ transplant rejection medications market?
What will be the Y-o-Y growth of the organ transplant rejection medications market between 2019 and 2027?
What is the influence of changing trends in technologies on the global organ transplant rejection medications market?
Will North America continue to remain the most profitable regional market for organ transplant rejection medication providers?
Which factors will impede the growth of the global organ transplant rejection medications market during the forecast period?
Which are the leading companies in the global organ transplant rejection medications market?
Research Methodology
A unique research methodology has been utilized by TMR to conduct a comprehensive research on the growth of the global organ transplant rejection medications market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary sources referred to by analysts during the production of the global organ transplant rejection medications market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who have contributed to the production of TMR’s study on the organ transplant rejection medications market as primary sources.
These primary and secondary sources have provided exclusive information during interviews, which serves as a validation from organ transplant rejection medications market leaders. Access to extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global organ transplant rejection medications market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global organ transplant rejection medications market more reliably and accurately.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Organ Transplant Rejection Medications Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Organ Transplant Rejection Medications Market Analysis and Forecast, 2017–2027
5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Mergers & Acquisitions
6. Global Organ Transplant Rejection Medications Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2027
6.3.1. Calcineurin Inhibitors
6.3.2. Antiproliferative Agents
6.3.3. mTOR Inhibitors
6.3.4. Antibodies
6.3.5. Steroids
6.4. Market Attractiveness, by Drug Class
7. Global Organ Transplant Rejection Medications Market Analysis and Forecast, by Transplant Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Transplant Type, 2017–2027
7.3.1. Kidney Transplant
7.3.2. Bone Marrow Transplant
7.3.3. Liver Transplant
7.3.4. Heart Transplant
7.3.5. Lung Transplant
7.3.6. Other Transplants
7.4. Market Attractiveness, by Transplant Type
8. Global Organ Transplant Rejection Medications Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global Organ Transplant Rejection Medications Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Organ Transplant Rejection Medications Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast, by Drug Class, 2017–2027
10.2.1. Calcineurin Inhibitors
10.2.2. Antiproliferative Agents
10.2.3. mTOR Inhibitors
10.2.4. Antibodies
10.2.5. Steroids
10.3. Market Value Forecast, by Transplant Type, 2017–2027
10.3.1. Kidney Transplant
10.3.2. Bone Marrow Transplant
10.3.3. Liver Transplant
10.3.4. Heart Transplant
10.3.5. Lung Transplant
10.3.6. Other Transplants
10.4. Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Transplant Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Organ Transplant Rejection Medications Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast, by Drug Class, 2017–2027
11.2.1. Calcineurin Inhibitors
11.2.2. Antiproliferative Agents
11.2.3. mTOR Inhibitors
11.2.4. Antibodies
11.2.5. Steroids
11.3. Market Value Forecast, by Transplant Type, 2017–2027
11.3.1. Kidney Transplant
11.3.2. Bone Marrow Transplant
11.3.3. Liver Transplant
11.3.4. Heart Transplant
11.3.5. Lung Transplant
11.3.6. Other Transplants
11.4. Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Transplant Type
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Organ Transplant Rejection Medications Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast, by Drug Class, 2017–2027
12.2.1. Calcineurin Inhibitors
12.2.2. Antiproliferative Agents
12.2.3. mTOR Inhibitors
12.2.4. Antibodies
12.2.5. Steroids
12.3. Market Value Forecast, by Transplant Type, 2017–2027
12.3.1. Kidney Transplant
12.3.2. Bone Marrow Transplant
12.3.3. Liver Transplant
12.3.4. Heart Transplant
12.3.5. Lung Transplant
12.3.6. Other Transplants
12.4. Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Transplant Type
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Organ Transplant Rejection Medications Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast, by Drug Class, 2017–2027
13.2.1. Calcineurin Inhibitors
13.2.2. Antiproliferative Agents
13.2.3. mTOR Inhibitors
13.2.4. Antibodies
13.2.5. Steroids
13.3. Market Value Forecast, by Transplant Type, 2017–2027
13.3.1. Kidney Transplant
13.3.2. Bone Marrow Transplant
13.3.3. Liver Transplant
13.3.4. Heart Transplant
13.3.5. Lung Transplant
13.3.6. Other Transplants
13.4. Market Value Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Transplant Type
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Organ Transplant Rejection Medications Market Analysis and Forecast
14.1. Introduction
14.2. Market Value Forecast, by Drug Class, 2017–2027
14.2.1. Calcineurin Inhibitors
14.2.2. Antiproliferative Agents
14.2.3. mTOR Inhibitors
14.2.4. Antibodies
14.2.5. Steroids
14.3. Market Value Forecast, by Transplant Type, 2017–2027
14.3.1. Kidney Transplant
14.3.2. Bone Marrow Transplant
14.3.3. Liver Transplant
14.3.4. Heart Transplant
14.3.5. Lung Transplant
14.3.6. Other Transplants
14.4. Market Value Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Transplant Type
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Top Players Operating in the Market
15.2. Company Profiles
15.2.1. GlaxoSmithKline plc
15.2.1.1. Company Overview
15.2.1.2. Company Financials
15.2.1.3. Growth Strategies
15.2.1.4. SWOT Analysis
15.2.2. Novartis AG
15.2.2.1. Company Overview
15.2.2.2. Company Financials
15.2.2.3. Growth Strategies
15.2.2.4. SWOT Analysis
15.2.3. F. Hoffmann-La Roche Ltd.
15.2.3.1. Company Overview
15.2.3.2. Company Financials
15.2.3.3. Growth Strategies
15.2.3.4. SWOT Analysis
15.2.4. Astellas Pharma, Inc.
15.2.4.1. Company Overview
15.2.4.2. Company Financials
15.2.4.3. Growth Strategies
15.2.4.4. SWOT Analysis
15.2.5. Pfizer, Inc.
15.2.5.1. Company Overview
15.2.5.2. Company Financials
15.2.5.3. Growth Strategies
15.2.5.4. SWOT Analysis
15.2.6. AbbVie, Inc.
15.2.6.1. Company Overview
15.2.6.2. Company Financials
15.2.6.3. Growth Strategies
15.2.6.4. SWOT Analysis
15.2.7. Allergan plc.
15.2.7.1. Company Overview
15.2.7.2. Company Financials
15.2.7.3. Growth Strategies
15.2.7.4. SWOT Analysis
15.2.8. Bristol-Myers Squibb Company (BMS)
15.2.8.1. Company Overview
15.2.8.2. Company Financials
15.2.8.3. Growth Strategies
15.2.8.4. SWOT Analysis
15.2.9. Sanofi
15.2.9.1. Company Overview
15.2.9.2. Company Financials
15.2.9.3. Growth Strategies
15.2.9.4. SWOT Analysis
List of TablesTable 01: Pipeline Analysis: Organ Transplant Rejection Medications Market
Table 02: Key Merger and Acquisitions
Table 03: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 04: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017–2027
Table 05: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 06: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 07: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 08: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017–2027
Table 09: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 10: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 11: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 12: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017–2027
Table 13: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 14: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 15: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 16: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017–2027
Table 17: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 18: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 19: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 20: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017–2027
Table 21: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 22: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 23: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 24: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017–2027
Table 25: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 26: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027